A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | HCPCS codes | Brand name | Generic name | HCPCS Description | Requirement | Requirement effective date | Clinical Category | |||||||||||||||||||
2 | J9264 | ABRAXANE | paclitaxel | Injection, paclitaxel protein-bound particles, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
3 | J3262 | ACTEMRA | tocilizumab | INJECTION, TOCILIZUMAB, 1 MG | PA Request | 1/1/2023 | Auto-inflammatory Conditions | |||||||||||||||||||
4 | J0800 | ACTHAR | corticotropin | Injection, corticotropin, up to 40 units | Precertification Notification | 1/1/2021 | Endocrine Disorders | |||||||||||||||||||
5 | J2504 | ADAGEN | pegademase bovine | Injection, pegademase bovine, 25 iu | Precertification Notification | 1/1/2021 | Enzyme Deficiency | |||||||||||||||||||
6 | J0791 | ADAKVEO | crizanlizumab-tmca | Inj crizanlizumab-tmca 5 mg | PA Request | 1/1/2023 | Sickle Cell Disease | |||||||||||||||||||
7 | J9042 | ADCETRIS | brentuximab | Brentuximab Vedotin, 1mg | PA Request | 1/1/2023 | Oncology | |||||||||||||||||||
8 | J9000 | ADRIAMYCIN | doxorubicin hcl | Injection, doxorubicin hydrochloride, 10 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
9 | J9190 | ADRUCIL | fluorouracil | Injection, fluorouracil, 500 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
10 | J0172 | ADUHELM | aducanumab-avwa | Injection, aducanumab-avwa, 2 mg | Exclusion: Medical Necessity Review Required | 1/1/2022 | Antidementia Agent | |||||||||||||||||||
11 | J7192 | ADVATE | factor viii | Factor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
12 | J7207 | ADYNOVATE | factor viii | Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
13 | J7210 | AFSTYLA | factor viii | Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
14 | J1454 | AKYNZEO | fosnetupitant / palonosetron | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Precertification Notification | 8/1/2022 | Anti-emetics | |||||||||||||||||||
15 | J1931 | ALDURAZYME | laronidase | Injection, laronidase, 0.1 mg | Precertification Notification | 1/1/2021 | Enzyme Deficiency | |||||||||||||||||||
16 | J9215 | ALFERON N | interferon, alfa-n3, (human leukocyte derived) | Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
17 | J0220 | Alglucosidase alfa | Alglucosidase alfa | Injection, alglucosidase alfa, 10 mg, not otherwise specified | PA Request | 10/1/2022 | Enzyme Deficiency | |||||||||||||||||||
18 | J9305 | ALIMTA | pemetrexed | Injection, pemetrexed, not otherwise specified, 10 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
19 | J9057 | ALIQOPA | copanlisib | Inj., copanlisib, 1 mg | PA Request | 1/1/2023 | Oncology | |||||||||||||||||||
20 | J9245 | ALKERAN | melphalan hcl | Injection, melphalan hydrochloride, not otherwise specified, 50 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
21 | J2469 | Aloxi | Palonosetron hcl | Injection, palonosetron hcl, 25 mcg | No PA/No Precert Required | N/A | Anti-emetics | |||||||||||||||||||
22 | J7186 | ALPHANATE | factor viii/von willebrand factor | Injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
23 | J7193 | ALPHANINE SD | factor ix | Factor ix (antihemophilic factor, purified, non-recombinant) per i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
24 | J7201 | ALPROLIX | factor ix | Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
25 | J7345 | AMELUZ | aminolevulinic acid hcl | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Precertification Notification | 1/1/2021 | Actinic Keratosis | |||||||||||||||||||
26 | J0225 | Amvuttra | Vutrisiran | Injection, vutrisiran, 1 mg | Not Covered | 5/1/23 | Neurotoxins | |||||||||||||||||||
27 | J0739 | Apretude | Cabotegravir | Injection, cabotegravir, 1 mg | Precertification Notification | 5/1/23 | HIV/AIDS | |||||||||||||||||||
28 | J0256 | ARALAST NP | alpha 1 proteinase inhibitor | Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg | Precertification Notification | 1/1/2021 | Enzyme Deficiency | |||||||||||||||||||
29 | J0881 | ARANESP | darbepoetin alfa | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Precertification Notification | 1/1/2021 | Anemia | |||||||||||||||||||
30 | J2430 | Aredia | Pamidronate disodium | Injection, pamidronate disodium, per 30 mg | No PA/No Precert Required | N/A | Osteoporosis | |||||||||||||||||||
31 | J9261 | ARRANON | nelarabine | Injection, nelarabine, 50 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
32 | J9017 | ARSENIC TRIOXIDE | arsenic trioxide | Injection, arsenic trioxide, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
33 | J9302 | ARZERRA | ofatumumab | INJECTION, OFATUMUMAB, 10 MG | PA Request | 1/1/2023 | Oncology | |||||||||||||||||||
34 | 90283 | ASCENIV | immune globulin | Immune globulin (IgIV), human, for intravenous use | Precertification Notification | 1/1/2021 | Immunodeficiency | |||||||||||||||||||
35 | J1554 | ASCENIV | immune globulin | Injection, immune globulin (asceniv), 500 mg | Precertification Notification | 1/1/2021 | Immunodeficiency | |||||||||||||||||||
36 | J9118 | ASPARLAS | calaspargase pegol-mknl | Injection, calaspargase pegol-mknl, 10 units | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
37 | J7196 | ATRYN | antithrombin | Injection, antithrombin recombinant, 50 i.u. | Precertification Notification | 1/1/2021 | Hereditary Antithrombin Deficiency | |||||||||||||||||||
38 | J9035 | AVASTIN | bevacizumab | Injection, bevacizumab, 10 mg | PA Request | 8/1/2022 | Oncology | |||||||||||||||||||
39 | J9035 | AVASTIN | bevacizumab | Injection, bevacizumab, 10mg | No PA required | 8/1/2022 | Ophthalmic Disorders | |||||||||||||||||||
40 | J3145 | AVEED | testosterone undecanoate | Injection, testosterone undecanoate, 1 mg | Precertification Notification | 1/1/2021 | Endocrine Disorders | |||||||||||||||||||
41 | Q5121 | Avsola | Infliximab-axxq | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | No PA/No Precert Required | N/A | Auto-inflammatory Conditions | |||||||||||||||||||
42 | J9025 | AZACITIDINE | azacitidine | Injection, azacitidine, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
43 | J9023 | BAVENCIO | avelumab | Injection, avelumab, 10 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
44 | 90585 | BCG VACCINE | bcg live | Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use | Precertification Notification | 1/1/2021 | Oncology/vaccine | |||||||||||||||||||
45 | J9032 | BELEODAQ | belinostat | Injection, belinostat, 10 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
46 | J9036 | BELRAPZO | bendamustine hcl | Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
47 | J9036 | BENDAMUSTINE HCL | bendamustine hcl | Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
48 | J9034 | BENDEKA | bendeka | Injection, bendamustine hcl (bendeka), 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
49 | J7195 | BENEFIX | factor ix | Injection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
50 | J0490 | BENLYSTA IV | belimumab | Injection, belimumab, 10 mg | PA Request | 1/1/2023 | Systemic Lupus Erythematosus (SLE) | |||||||||||||||||||
51 | J0179 | BEOVU | Brolucizumab | Injection, brolucizumab-dbll, 1 mg | PA Request | 10/1/2022 | Macular Degeneration | |||||||||||||||||||
52 | J0597 | BERINERT | c1 esterase inhibitor | Injection, c-1 esterase inhibitor (human), berinert, 10 units | Precertification Notification | 1/1/2021 | Hereditary Angioedema | |||||||||||||||||||
53 | J9229 | BESPONSA | inotuzumab ozogamicin | Injection, inotuzumab ozogamicin, 0.1 mg | PA Request | 1/1/2023 | Oncology | |||||||||||||||||||
54 | Q5126 | Bevacizumab (Alymsys) | Bevacizumab-maly | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
55 | Q5118 | Bevacizumab (Zirabev) | Bevacizumab-bvzr | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
56 | Q5107 | Bevacizumab (Mvasi) | Bevacizumab-awwb | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
57 | Q5129 | Bevacizumab (Vegzelma) | Bevacizumab-adcd | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
58 | J9050 | BICNU | carmustine | Injection, carmustine, 100 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
59 | 90283 | BIVIGAM | immune globulin | Immune globulin (IgIV), human, for intravenous use | Precertification Notification | 1/1/2021 | Immunodeficiency | |||||||||||||||||||
60 | J1556 | BIVIGAM | immune globulin | Injection, immune globulin (bivigam), 500 mg | Precertification Notification | 1/1/2021 | Immunodeficiency | |||||||||||||||||||
61 | J9037 | BLENREP | belantamab mafodotin-blmf | Injection, belantamab mafodotin-blmf, 0.5 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
62 | J9040 | BLEOMYCIN SULFATE | bleomycin sulfate | Injection, bleomycin sulfate, 15 units | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
63 | J9039 | BLINCYTO | blinatumomab | Injection, blinatumomab, 1 microgram | PA Request | 1/1/2022 | Oncology | |||||||||||||||||||
64 | J1740 | Boniva | Ibandronate sodium | Injection, ibandronate sodium, 1 mg | No PA/No Precert Required | N/A | Osteoporosis | |||||||||||||||||||
65 | J9046 | Bortezomib (Velcade Biosimilar) | Bortezomib | Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg ((biosimilar for VELCADE) | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
66 | J9048 | Bortezomib (Velcade Biosimilar) | Bortezomib | Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg (biosimilar for VELCADE) | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
67 | J9049 | Bortezomib (Velcade Biosimilar) | Bortezomib | Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg (biosimilar for VELCADE) | No PA/No Precert Required | N/A | Oncology | |||||||||||||||||||
68 | J0585 | BOTOX | onabotulinumtoxina | Injection, onabotulinumtoxina, 1 unit | PA Request | 6/1/2022 | Neurotoxins | |||||||||||||||||||
69 | J0567 | BRINEURA | cerliponase alfa | Injection, cerliponase alfa, 1 mg | PA Request | 1/1/2022 | Enzyme Deficiency | |||||||||||||||||||
70 | J0594 | BUSULFAN | busulfan | injection, busulfan, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
71 | Q5124 | Byooviz | Ranibizumab-nuna | Injection, ranibizumab-nuna, biosimilar, (byooviz) | No PA/No Precert Required | N/A | Macular Degeneration | |||||||||||||||||||
72 | J9206 | CAMPTOSAR | irinotecan | Injection, irinotecan, 20 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
73 | J9045 | CARBOPLATIN | carboplatin | Injection, carboplatin, 50 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
74 | J9050 | CARMUSTINE | carmustine | Injection, carmustine, 100 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
75 | J2724 | CEPROTIN | protein c concentrate, IV, human | Injection, protein c concentrate, intravenous, human, 10 iu | Precertification Notification | 1/1/2021 | Severe Congenital Protein C Deficiency | |||||||||||||||||||
76 | J1786 | CEREZYME | Imiglucerase | Injection, imiglucerase, 10 units | PA Request | 10/1/2022 | Enzyme Deficiency | |||||||||||||||||||
77 | J0740 | CIDOFOVIR | cidofovir | Injection, cidofovir, 375 mg | Precertification Notification | 1/1/2021 | Anti-Infective Therapy | |||||||||||||||||||
78 | J0717 | CIMZIA | certolizumab | Certolizumab pegol inj 1mg | PA Request | 1/1/2023 | Auto-inflammatory Conditions | |||||||||||||||||||
79 | J2786 | CINQAIR | reslizumab | Injection, reslizumab, 1 mg | PA Request | 8/1/2022 | Asthma | |||||||||||||||||||
80 | J0598 | CINRYZE | c1 esterase inhibitor | Injection, c-1 esterase inhibitor (human), cinryze, 10 units | Precertification Notification | 1/1/2021 | Hereditary Angioedema | |||||||||||||||||||
81 | J9060 | CISPLATIN | cisplatin | Injection, cisplatin, powder or solution, 10 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
82 | J9065 | CLADRIBINE | cladribine | Injection, cladribine, per 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
83 | J9027 | CLOFARABINE | clofarabine | Injection, clofarabine, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
84 | J9027 | CLOLAR | clofarabine | Injection, clofarabine, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
85 | J7175 | COAGADEX | factor x | Injection, factor x, (human), 1 i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
86 | J7180 | CORIFACT | factor xiii | Injection, factor xiii (antihemophilic factor, human), 1 i.u. | Precertification Notification | 1/1/2021 | Hemophilia | |||||||||||||||||||
87 | J9120 | COSMEGEN | dactinomycin | Injection, dactinomycin, 0.5 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
88 | J0584 | CRYSVITA | burosumab | Injection, burosumab-twza 1 mg | PA Request | 1/1/2023 | Metabolic Conditions | |||||||||||||||||||
89 | J1551 | CUTAQUIG | immune globulin (cutaquig) | Injection, immune globulin (cutaquig), 100 mg | Not Covered | 7/1/2022 | Immunodeficiency | |||||||||||||||||||
90 | 90284 | CUVITRU | immune globulin | Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each | Precertification Notification | 1/1/2021 | Immunodeficiency | |||||||||||||||||||
91 | J1555 | CUVITRU | immune globulin | Injection, immune globulin (cuvitru), 100 mg | Precertification Notification | 1/1/2021 | Immunodeficiency | |||||||||||||||||||
92 | J9070 | CYCLOPHOSPHAMIDE | cyclophosphamide | Cyclophosphamide, 100 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
93 | J9071 | CYCLOPHOSPHAMIDE | cyclophosphamide | Injection, cyclophosphamide, (auromedics), 5 mg | Precertification Notification | 8/1/2022 | Oncology | |||||||||||||||||||
94 | J9308 | CYRAMZA | ramucirumab | Injection, ramucirumab, 5 mg | PA Request | 1/1/2023 | Oncology | |||||||||||||||||||
95 | J9100 | CYTARABINE | cytarabine | Injection, cytarabine, 100 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
96 | J1570 | CYTOVENE | ganciclovir sodium | Injection, ganciclovir sodium, 500 mg | Precertification Notification | 1/1/2021 | Anti-Infective Therapy | |||||||||||||||||||
97 | J9130 | DACARBAZINE | dacarbazine | Dacarbazine, 100 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
98 | J0894 | DACOGEN | decitabine | Injection, decitabine, 1 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
99 | J9120 | DACTINOMYCIN | dactinomycin | Injection, dactinomycin, 0.5 mg | Precertification Notification | 1/1/2021 | Oncology | |||||||||||||||||||
100 | J9348 | DANYELZA | naxitamab-gqgk | Injection, naxitamab-gqgk, 1 mg | PA Request | 1/1/2022 | Oncology |